A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Maraviroc (SELZENTRY)

CCR5 Co-receptor Antagonist class · 4 generic manufacturers · 8 ANDAs filed at FDA.

First FDA approval2011-05-16
Generic availableYes · 4 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$32.6M in CY2024 Part D spend24K claims · 4K beneficiaries · 329 plans surveyed

Lowest NADAC
$8.96/unit
7 NDCs benchmarked, lowest of all strengths.
Average NADAC
$11.76
Across all dosage forms in distribution.
Highest NADAC
$28.00
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Maraviroc used for?

Maraviroc is a CCR5 Co-receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Maraviroc?

Yes. 8 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Maraviroc?

Across 329 Part D plans, Maraviroc averages $11.76/unit (NADAC). Lowest available: $8.96/unit. Highest in distribution: $28.00/unit.

Is Maraviroc on the FDA shortage list?

Maraviroc has been discontinued by its manufacturer(s).

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (7 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.